Literature DB >> 26721686

In vivo gene editing in dystrophic mouse muscle and muscle stem cells.

Mohammadsharif Tabebordbar1,2, Kexian Zhu1,3, Jason K W Cheng1, Wei Leong Chew2,4, Jeffrey J Widrick5, Winston X Yan6,7, Claire Maesner1, Elizabeth Y Wu1, Ru Xiao8, F Ann Ran6,7, Le Cong6,7, Feng Zhang6,7, Luk H Vandenberghe8, George M Church4, Amy J Wagers1.   

Abstract

Frame-disrupting mutations in the DMD gene, encoding dystrophin, compromise myofiber integrity and drive muscle deterioration in Duchenne muscular dystrophy (DMD). Removing one or more exons from the mutated transcript can produce an in-frame mRNA and a truncated, but still functional, protein. In this study, we developed and tested a direct gene-editing approach to induce exon deletion and recover dystrophin expression in the mdx mouse model of DMD. Delivery by adeno-associated virus (AAV) of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 endonucleases coupled with paired guide RNAs flanking the mutated Dmd exon23 resulted in excision of intervening DNA and restored the Dmd reading frame in myofibers, cardiomyocytes, and muscle stem cells after local or systemic delivery. AAV-Dmd CRISPR treatment partially recovered muscle functional deficiencies and generated a pool of endogenously corrected myogenic precursors in mdx mouse muscle.
Copyright © 2016, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26721686      PMCID: PMC4924477          DOI: 10.1126/science.aad5177

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  25 in total

Review 1.  Skeletal muscle degenerative diseases and strategies for therapeutic muscle repair.

Authors:  Mohammadsharif Tabebordbar; Eric T Wang; Amy J Wagers
Journal:  Annu Rev Pathol       Date:  2012-11-01       Impact factor: 23.472

2.  Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA.

Authors:  Chengzu Long; John R McAnally; John M Shelton; Alex A Mireault; Rhonda Bassel-Duby; Eric N Olson
Journal:  Science       Date:  2014-08-14       Impact factor: 47.728

3.  A robust and high-throughput Cre reporting and characterization system for the whole mouse brain.

Authors:  Linda Madisen; Theresa A Zwingman; Susan M Sunkin; Seung Wook Oh; Hatim A Zariwala; Hong Gu; Lydia L Ng; Richard D Palmiter; Michael J Hawrylycz; Allan R Jones; Ed S Lein; Hongkui Zeng
Journal:  Nat Neurosci       Date:  2009-12-20       Impact factor: 24.884

4.  Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals.

Authors:  M Koenig; E P Hoffman; C J Bertelson; A P Monaco; C Feener; L M Kunkel
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

5.  Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection.

Authors:  Carmela Zincarelli; Stephen Soltys; Giuseppe Rengo; Joseph E Rabinowitz
Journal:  Mol Ther       Date:  2008-04-15       Impact factor: 11.454

6.  Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion.

Authors:  Q L Lu; G E Morris; S D Wilton; T Ly; O V Artem'yeva; P Strong; T A Partridge
Journal:  J Cell Biol       Date:  2000-03-06       Impact factor: 10.539

7.  In vivo genome editing using Staphylococcus aureus Cas9.

Authors:  F Ann Ran; Le Cong; Winston X Yan; David A Scott; Jonathan S Gootenberg; Andrea J Kriz; Bernd Zetsche; Ophir Shalem; Xuebing Wu; Kira S Makarova; Eugene V Koonin; Phillip A Sharp; Feng Zhang
Journal:  Nature       Date:  2015-04-01       Impact factor: 49.962

8.  Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.

Authors:  Maria Kinali; Virginia Arechavala-Gomeza; Lucy Feng; Sebahattin Cirak; David Hunt; Carl Adkin; Michela Guglieri; Emma Ashton; Stephen Abbs; Petros Nihoyannopoulos; Maria Elena Garralda; Mary Rutherford; Caroline McCulley; Linda Popplewell; Ian R Graham; George Dickson; Matthew J A Wood; Dominic J Wells; Steve D Wilton; Ryszard Kole; Volker Straub; Kate Bushby; Caroline Sewry; Jennifer E Morgan; Francesco Muntoni
Journal:  Lancet Neurol       Date:  2009-08-25       Impact factor: 44.182

9.  Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human.

Authors:  Marcella Neri; Silvia Torelli; Sue Brown; Isabella Ugo; Patrizia Sabatelli; Luciano Merlini; Pietro Spitali; Paola Rimessi; Francesca Gualandi; Caroline Sewry; Alessandra Ferlini; Francesco Muntoni
Journal:  Neuromuscul Disord       Date:  2007-09-07       Impact factor: 4.296

10.  Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice.

Authors:  Yusuke Echigoya; Yoshitsugu Aoki; Bailey Miskew; Dharminder Panesar; Aleksander Touznik; Tetsuya Nagata; Jun Tanihata; Akinori Nakamura; Kanneboyina Nagaraju; Toshifumi Yokota
Journal:  Mol Ther Nucleic Acids       Date:  2015-02-03       Impact factor: 10.183

View more
  432 in total

1.  AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice.

Authors:  Chady H Hakim; Nalinda B Wasala; Christopher E Nelson; Lakmini P Wasala; Yongping Yue; Jacqueline A Louderman; Thais B Lessa; Aihua Dai; Keqing Zhang; Gregory J Jenkins; Michael E Nance; Xiufang Pan; Kasun Kodippili; N Nora Yang; Shi-Jie Chen; Charles A Gersbach; Dongsheng Duan
Journal:  JCI Insight       Date:  2018-12-06

2.  Genetic engineering: In vivo genome editing - growing in strength.

Authors:  Linda Koch
Journal:  Nat Rev Genet       Date:  2016-01-19       Impact factor: 53.242

3.  Neuromuscular disease: Genome editing shows promise in an in vivo model of Duchenne muscular dystrophy.

Authors:  Heather Wood
Journal:  Nat Rev Neurol       Date:  2016-01-18       Impact factor: 42.937

Review 4.  Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials.

Authors:  Yuko Shimizu-Motohashi; Shouta Miyatake; Hirofumi Komaki; Shin'ichi Takeda; Yoshitsugu Aoki
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

5.  Questions Answered and Unanswered by the First CRISPR Editing Study in a Canine Model of Duchenne Muscular Dystrophy.

Authors:  Nalinda B Wasala; Chady H Hakim; Shi-Jie Chen; N Nora Yang; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2019-02-26       Impact factor: 5.695

Review 6.  Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.

Authors:  Majid Lotfinia; Meghdad Abdollahpour-Alitappeh; Behzad Hatami; Mohammad Reza Zali; Morteza Karimipoor
Journal:  Clin Exp Med       Date:  2019-05-03       Impact factor: 3.984

Review 7.  Therapeutic potential of combined viral transduction and CRISPR/Cas9 gene editing in treating neurodegenerative diseases.

Authors:  Joshua Kuruvilla; Andrew Octavian Sasmita; Anna Pick Kiong Ling
Journal:  Neurol Sci       Date:  2018-08-03       Impact factor: 3.307

8.  Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome.

Authors:  Chang Xie; Ya-Ping Zhang; Lu Song; Jie Luo; Wei Qi; Jialu Hu; Danbo Lu; Zhen Yang; Jian Zhang; Jian Xiao; Bin Zhou; Jiu-Lin Du; Naihe Jing; Yong Liu; Yan Wang; Bo-Liang Li; Bao-Liang Song; Yan Yan
Journal:  Cell Res       Date:  2016-08-30       Impact factor: 25.617

Review 9.  Public health applications of CRISPR: How children's health can benefit.

Authors:  Vivian S Vigliotti; Isabel Martinez
Journal:  Semin Perinatol       Date:  2018-10-02       Impact factor: 3.300

10.  Optimizing CRISPR/Cas9 technology for precise correction of the Fgfr3-G374R mutation in achondroplasia in mice.

Authors:  Kai Miao; Xin Zhang; Sek Man Su; Jianming Zeng; Zebin Huang; Un In Chan; Xiaoling Xu; Chu-Xia Deng
Journal:  J Biol Chem       Date:  2018-11-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.